千金药业拟6.23亿元收购千金湘江药业及千金协力药业股权，交易方案获股东大会通过

中访网数据2025-07-05

中访网数据株洲千金药业股份有限公司(以下简称“千金药业”)近日披露重大资产重组进展，拟以发行股份及支付现金方式收购千金湘江药业和千金协力药业部分股权，交易总价6.23亿元，其中股份对价6.20亿元(占比99.4%)，现金对价362.54万元(占比0.6%)。该交易方案已于2025年3月14日获股东大会审议通过，关联股东株洲市国有资产投资控股集团有限公司(株洲国投)回避表决。核心内容： 1. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549311805?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-05 08:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549311805","market":"sh","top_or_hot":-1,"title":"千金药业拟6.23亿元收购千金湘江药业及千金协力药业股权，交易方案获股东大会通过","media":"中访网数据","content":"<div>\n<p>中访网数据  株洲千金药业股份有限公司(以下简称“千金药业”)近日披露重大资产重组进展，拟以发行股份及支付现金方式收购千金湘江药业和千金协力药业部分股权，交易总价6.23亿元，其中股份对价6.20亿元(占比99.4%)，现金对价362.54万元(占比0.6%)。该交易方案已于2025年3月14日获股东大会审议通过，关联股东株洲市国有资产投资控股集团有限公司(株洲国投)回避表决。核心内容： 1. ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705085326953719bf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>千金药业拟6.23亿元收购千金湘江药业及千金协力药业股权，交易方案获股东大会通过</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n千金药业拟6.23亿元收购千金湘江药业及千金协力药业股权，交易方案获股东大会通过\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-05 08:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705085326953719bf&s=b><strong>中访网数据</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中访网数据  株洲千金药业股份有限公司(以下简称“千金药业”)近日披露重大资产重组进展，拟以发行股份及支付现金方式收购千金湘江药业和千金协力药业部分股权，交易总价6.23亿元，其中股份对价6.20亿元(占比99.4%)，现金对价362.54万元(占比0.6%)。该交易方案已于2025年3月14日获股东大会审议通过，关联股东株洲市国有资产投资控股集团有限公司(株洲国投)回避表决。核心内容： 1. ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705085326953719bf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600479","symbol_name":"千金药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705085326953719bf&s=b","article_id":"2549311805","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705085326953719bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549311805","pubTimestamp":1751676076,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中访网数据  株洲千金药业股份有限公司近日披露重大资产重组进展，拟以发行股份及支付现金方式收购千金湘江药业和千金协力药业部分股权，交易总价6.23亿元，其中股份对价6.20亿元，现金对价362.54万元。该交易方案已于2025年3月14日获股东大会审议通过，关联股东株洲市国有资产投资控股集团有限公司回避表决。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600479":"千金药业","BK0239":"医药制造","BK0186":"小盘成长"},"translate_title":"Qianjin Pharmaceutical plans to acquire the equity of Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical for 623 million yuan, and the transaction plan was approved by the shareholders' meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600479":1},"content_text":"中访网数据  株洲千金药业股份有限公司(以下简称“千金药业”)近日披露重大资产重组进展，拟以发行股份及支付现金方式收购千金湘江药业和千金协力药业部分股权，交易总价6.23亿元，其中股份对价6.20亿元(占比99.4%)，现金对价362.54万元(占比0.6%)。该交易方案已于2025年3月14日获股东大会审议通过，关联股东株洲市国有资产投资控股集团有限公司(株洲国投)回避表决。核心内容： 1. 交易结构：标的资产为千金湘江药业8%股权及千金协力药业40%股权，交易完成后千金药业对两家子公司的持股比例将分别提升至93%和100%。 2. 资金安排：上市公司货币资金充足(2024年末余额13.44亿元)，现金支付占比极低，主要采用发行股份方式以保障战略投入需求。 3. 国资审批：评估结果已获株洲国投备案，株洲市产业发展投资控股集团确认审批程序合规完成。 4. 业绩承诺：株洲国投作为补偿方签署协议，补充条款明确不可抗力情形下仍需履行补偿义务，符合监管要求。 5. 历史代持清理：标的公司千金协力药业曾存在的股权代持已全部解除，15名自然人股东出资来源合法，无纠纷风险。影响分析： 本次交易将强化千金药业对核心子公司的控制权，整合医药工业资源。标的公司2024年合计贡献营收超10亿元，交易后有望提升上市公司盈利能力。独立财务顾问及律师认为方案符合重组管理办法，后续需经上交所审核及证监会注册。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549311805","isCrawlerRequest":true}